A Dendritic Cell Cancer Vaccine of Matured Phenotype Downregulates Peripheral Regulatory T Cell Frequency and Identification of Plasma Protein Profiles Predicting Vaccine Efficacy - Results from a Phase II Study

被引：0
|
作者：
Wang, Who-Whong [1 ]
Chia, John [1 ]
Tan, Sze Huey [1 ]
Zocca, Mai-Britt [2 ]
Claesson, Mogens H. [3 ]
Toh, Han Chong [1 ]
机构：
[1] Natl Canc Ctr, Singapore, Singapore
[2] Dandrit Biotech A S, Copenhagen, Denmark
[3] Univ Copenhagen, Copenhagen, Denmark
来源：
MOLECULAR THERAPY | 2009年 / 17卷
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：S208 / S208
页数：1
相关论文
共 50 条
  • [41] Phase II trial of therapeutic vaccine consisting of autologous dendritic cells loaded with autologous tumor cell antigens from self-renewing cancer cells in patients with newly diagnosed glioblastoma
    Bota, Daniela
    Piccioni, David
    LaRocca, Renato
    Duma, Christopher
    Aiken, Robert
    Kesari, Santosh
    Carrillo, Jose
    Taylor, Thomas
    Hsieh, Candace
    Nistor, Gabriel
    Dillman, Robert
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [42] Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomized, neoadjuvant phase-II study (ABCSG-34)
    Singer, C. F.
    Pfeiler, G.
    Hubalek, M.
    Bartsch, R.
    Stoeger, H.
    Pichler, A.
    Petru, E.
    Greil, R.
    Rudas, M.
    Tea, M-KM
    Wette, V.
    Petzer, A. L.
    Sevelda, P.
    Egle, D.
    Dubsky, P. C.
    Balic, M.
    Tinchon, C.
    Bago-Horvath, Z.
    Frantal, S.
    Michael, G.
    CANCER RESEARCH, 2017, 77
  • [43] Phase I/II study of a peptide-based COVID-19 vaccine to induce T-cell responses against SARS-CoV-2 in cancer patients with B-cell deficiency
    Heitmann, J.
    Tandler, C.
    Marconato, M.
    Habibzade, T.
    Rittig, S. M.
    Tegeler, C. M.
    Nelde, A.
    Maringer, Y.
    Jaeger, S.
    Denk, M.
    Richter, M.
    Oezbek, M. T.
    Wiesmueller, K. H.
    Bauer, J.
    Rieht, J.
    Wacker, M.
    Schroeder, S.
    Hoerber, S.
    Peter, A.
    Meisner, C.
    Fischer, I.
    Loeffler, M. W.
    Peuker, C. A.
    Habringer, S.
    Goetze, T. O.
    Jaeger, E.
    Rammensee, H. G.
    Salih, H. R.
    Walz, J. S.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 262 - 263
  • [44] Enhancement of vaccine-mediated antitumor immunity in renal cell carcinoma (RCC) patients after in vivo depletion of regulatory T cells. Results from a phase-1 clinical trial
    Dannull, J
    Su, Z
    Kuebler, HR
    Yang, BK
    Coleman, D
    Yancey, D
    Zhang, AJ
    Dahm, P
    Vieweg, J
    JOURNAL OF UROLOGY, 2006, 175 (04): : 130 - 130
  • [45] Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
    Coiffier, Bertrand
    Pro, Barbara
    Prince, H. Miles
    Foss, Francine
    Sokol, Lubomir
    Greenwood, Matthew
    Caballero, Dolores
    Borchmann, Peter
    Morschhauser, Franck
    Wilhelm, Martin
    Pinter-Brown, Lauren
    Padmanabhan, Swaminathan
    Shustov, Andrei
    Nichols, Jean
    Carroll, Susan
    Balser, John
    Balser, Barbara
    Horwitz, Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (06) : 631 - 636
  • [46] Phase I/II Study of Adoptive T Cell Therapy Following In Vivo Priming with a HER2 Peptide-Based Vaccine in Patients with Stage IV Breast Cancer.
    Parker, S. L.
    Higgins, D. M.
    Childs, J. S.
    Dang, Y.
    Guthrie, K. A.
    Disis, M. L.
    Salazar, L. G.
    Coveler, A.
    CANCER RESEARCH, 2011, 71
  • [47] Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer
    Barve, Minal
    Bender, James
    Senzer, Neil
    Cunningham, Casey
    Greco, F. Anthony
    McCune, David
    Steis, Ronald
    Khong, Hung
    Richards, Donald
    Stephenson, Joe
    Ganesa, Prasanthi
    Nemunaitis, Jackie
    Ishioka, Glenn
    Pappen, Beena
    Nemunaitis, Michael
    Morse, Michael
    Mills, Bonnie
    Maples, Phillip B.
    Sherman, Jeffrey
    Nemunaitis, John J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (27) : 4418 - 4425
  • [48] VXM01, an oral T-cell vaccine targeting the tumor vasculature: Results from a randomized, controlled, first-in-man study in pancreatic cancer patients.
    Schmitz-Winnenthal, Friedrich Hubertus
    Grenacher, Lars
    Friedrich, Tobias
    Lubenau, Heinz
    Springer, Marco
    Breiner, Klaus M.
    Hohmann, Nicolas
    Haefeli, Walter E.
    Mikus, Gerd
    Weitz, Juergen
    Ulrich, Alexis
    Buechler, Markus W.
    Knebel, Philip
    Schmidt, Thomas
    Ge, Yingzi
    Niethammer, Andreas G.
    Beckhove, Philipp
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [49] A Phase II Study Of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) As Front Line Therapy For Patients With Peripheral T-Cell Lymphoma (PTCL): Preliminary Results From The T-Cell Consortium Trial
    Advani, Ranjana H.
    Ansell, Stephen M.
    Lechowicz, Mary J.
    Beaven, Anne W.
    Loberiza, Fausto R., Jr.
    Carson, Kenneth R.
    Evens, Andrew M.
    Foss, Francine M.
    Horwitz, Steven M.
    Pro, Barbara
    Pinter-Brown, Lauren
    Smith, Sonali M.
    Shustov, Andrei R.
    Savage, Kerry J.
    Vose, Julie M.
    BLOOD, 2013, 122 (21)
  • [50] A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy For Patients With Peripheral T-Cell Lymphoma (PTCL): Preliminary Results From the T-Cell Consortium Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2014, 12 (02) : 6 - 7
12345